Precision medicines are evolving rapidly with impactful application in rare disease clinical research, including Amyotrophic Lateral Sclerosis (ALS), one of the most prominently positioned rare diseases. Successfully bringing cutting-edge precision medicines to market to meet unmet patient needs requires well-structured clinical strategies that transition therapies from discovery to the clinic. 

In our latest therapeutic spotlight, ICON’s experts explore the evolving therapeutic landscape of precision medicine with a special focus on the unique application in ALS. We outline key considerations for developing patient-centric, streamlined precision medicine programs that promote patient engagement, improve protocol adherence and reduce dropout rates – ultimately accelerating the delivery of meaningful therapies to patients.

• Critical front-end considerations for precision medicine development in rare diseases
• The importance of early engagement for commercial success and enablement of patient access and post market approval
• How patient-centric approaches reduce the burden on patients and improve trial outcomes
• Key success factors for developing ALS therapies with greater impact

Explore how we are advancing the future of precision medicine for ALS patients.